Last reviewed · How we verify

NCT05388708: ASCEND

ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)

Recruiting now Last updated 24 December 2025
What this trial tests

trial testing ECMO support in Acute Respiratory Distress Syndrome in 550 participants. Currently enrolling.

Timeline
4 February 2021
Primary endpoint
30 September 2027
30 September 2027

Quick facts

Lead sponsorUniversity of Michigan
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment550
Start date4 February 2021
Primary completion30 September 2027
Estimated completion30 September 2027
Sites99 locations across Italy, Colombia, New Zealand, Chile, Sweden, United Kingdom, Canada, Australia

Drugs / interventions tested

Conditions studied

Sponsor

University of Michigan

Who can join

Adults 14 Days to 20, any sex, with Acute Respiratory Distress Syndrome or Extracorporeal Membrane Oxygenation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatric intensive care unit. The second objective is to compare short and long-term patient outcomes in two groups of children: one group managed with a mechanical ventilation protocol that reserves the use of extracorporeal membrane oxygenation (ECMO) until protocol failure to another group supported on ECMO per usual care.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome.
    Kneyber MCJ, Khemani RG, Bhalla A, Blokpoel RGT, et al · · 2023 · cited 25× · PMID 36566767 · DOI 10.1016/s2213-2600(22)00483-0
  2. ECMO-induced coagulopathy: strategic initiatives for research and clinical practice (a workshop report of the NHLBI).
    Levy JH, Alexander PMA, Wolberg AS, McCarty OJT, et al · · 2025 · cited 11× · PMID 40766281 · DOI 10.1016/j.bvth.2025.100064
  3. Definitions of adverse events associated with extracorporeal membrane oxygenation in children: results of an international Delphi process from the ECMO-CENTRAL ARC.
    Alexander PMA, Di Nardo M, Combes A, Vogel AM, et al · · 2024 · cited 7× · PMID 39299748 · DOI 10.1016/s2352-4642(24)00132-9

Verify or expand the search:

Other recruiting trials for Acute Respiratory Distress Syndrome

Currently open trials in the same condition.

Other University of Michigan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05388708.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing